Key statistics
On Friday, Vanda Pharmaceuticals Inc (VNDA:NMQ) closed at 7.57, -21.15% below its 52-week high of 9.60, set on Dec 31, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.37 |
|---|---|
| High | 7.72 |
| Low | 7.30 |
| Bid | 7.50 |
| Offer | 8.04 |
| Previous close | 7.23 |
| Average volume | 934.73k |
|---|---|
| Shares outstanding | 59.10m |
| Free float | 54.84m |
| P/E (TTM) | -- |
| Market cap | 427.27m USD |
| EPS (TTM) | -1.43 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
- Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
- Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
More ▼
